Sapropterin Overview
Sapropterin dihydrochloride (Kuvan), approved for treating phenylketonuria (PKU), reduces blood phenylalanine levels in responsive patients. Complete symptom relief isn't a standard endpoint in PKU trials, as the condition requires lifelong management rather than full symptom elimination. Trials measured responsiveness by phenylalanine reduction (≥30% at specific doses) rather than complete relief.[1]
Key Clinical Trial Results on Responsiveness
In pivotal trials (e.g., KUV001, KUV002):
- 56% of patients (20/36) in the 20 mg/kg/day group showed ≥30% phenylalanine reduction.
- 41% (15/37) in the 10 mg/kg/day group responded similarly.
No trial reported "complete symptom relief"; instead, responsive patients had mean phenylalanine drops of 34-37%.[1][2]
Across pooled adult/child data (n=242):
- Overall response rate: 51% (123 patients).
- Highest responders (high-dose group): up to 66%.[1]
| Trial | Dose | Responsive Patients (≥30% Phe reduction) | Total Patients |
|-------|------|------------------------------------------|---------------|
| KUV001 | 20 mg/kg/day | 20 | 36 |
| KUV001 | 10 mg/kg/day | 15 | 37 |
| KUV002 | 20 mg/kg/day | 29 | 48 |
| Pooled | Various | 123 | 242[1][2] |
What Counts as Symptom Relief in PKU?
PKU symptoms (neurocognitive issues, behavioral problems) improve indirectly via phenylalanine control. Responsive patients maintained lower levels long-term (up to 6 years in extensions), with some achieving normal-range Phe (<360 μmol/L), but zero patients had documented complete resolution.[2][3]
Long-Term Data and Real-World Use
Extension studies (n=131 responsive patients, up to 8 years):
- 90% remained responsive.
- 84% kept Phe <600 μmol/L.
No complete symptom relief quantified; benefits were sustained Phe control, not eradication.[3]
Patient Subgroups and Limitations